Lea Eslava-Kim, PharmD, Author at MPR - Page 2 of 50

Lea Eslava-Kim, PharmD

Lea Eslava-Kim, PharmD, is a Drug Information Specialist for MPR. She received her doctorate in pharmacy from the Ernest Mario School of Pharmacy, Rutgers University and completed her pharmacy residency at Clara Maass Medical Center. She is a licensed pharmacist.

All articles by Lea Eslava-Kim, PharmD

Survival Benefit Compared With Immune Checkpoint Inhibitors in NSCLC

Pembrolizumab plus chemotherapy demonstrated the greatest survival benefit compared with other immune checkpoint inhibitors (ICIs) across all PD-L1 expression levels in the first-line treatment of advanced non-small cell lung cancer (NSCLC), according to a meta-analysis presented at the IASLC 2019 World Conference on Lung Cancer. Randomized clinical trials evaluating first-line ICI alone or in combination…

Selpercatinib Promising in RET Fusion-Positive NSCLC

Treatment with selpercatinib (LOXO-292) was associated with high objective response rate (ORR) in heavily pretreated patients with RET fusion-positive non-small cell lung cancer (NSCLC), according to research presented at the IASLC 2019 World Conference on Lung Cancer. Researchers from Memorial Sloan Kettering Cancer Center presented data from the LIBRETTO-001 (LOXO-292 Investigated to Block RETaltered Tumors)…

Durvalumab Plus Chemotherapy Improves Overall Survival in Extensive-Stage SCLC

Durvalumab added to standard-of-care (SoC) chemotherapy demonstrated significantly improved overall survival (OS) in treatment-naive patients with extensive-stage small cell lung cancer (SCLC), according to a phase 3 study presented at the IASLC 2019 World Conference on Lung Cancer. The CASPIAN trial was a randomized, open-label, multicenter, global, phase 3 study evaluating durvalumab in combination with…

Do BMI, Age Affect Clinical Response to Immune Checkpoint Inhibitors in Patients With NSCLC?

Obesity and age do not appear to influence the survival of patients with non-small cell lung cancer (NSCLC) treated with programmed death receptor-1 (PD-1)/programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitors (ICI), according to an analysis presented at the IASLC 2019 World Conference on Lung Cancer. To better understand how age and body mass…